Mostrar el registro sencillo

dc.contributor.authorSanturtún Zarrabeitia, Maite es_ES
dc.contributor.authorMediavilla-Martínez, Evaes_ES
dc.contributor.authorVega, Ana I.es_ES
dc.contributor.authorGallego, Nataliaes_ES
dc.contributor.authorHeath, Karen E.es_ES
dc.contributor.authorTenorio, Jair A.es_ES
dc.contributor.authorLapunzina, Pabloes_ES
dc.contributor.authorRiancho Zarrabeitia, Leyrees_ES
dc.contributor.authorRiancho Moral, José Antonio es_ES
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2022-12-02T15:45:21Z
dc.date.available2022-12-02T15:45:21Z
dc.date.issued2022-08-11es_ES
dc.identifier.issn1664-2392es_ES
dc.identifier.urihttps://hdl.handle.net/10902/26812
dc.description.abstractBackground: Low serum alkaline phosphatase levels are the hallmark of hypophosphatasia, a disorder due to pathogenic variants of the ALPL gene. However, some patients do not carry ALPL variants and the cause of low alkaline phosphatase remains unknown. We aimed to determine health-related quality of life in adults with low alkaline phosphatase and explore the differences between patients with and without ALPL mutations. Methods: We studied 35 adult patients with persistently low alkaline phosphatase unrelated to secondary acquired causes who had ALPL sequenced, and 35 controls of similar age. Three questionnaires about body pain (Brief Pain Inventory, BPI), physical disability (Health Assessment Questionnaire Disability Index, HAQ-DI), and health-related quality of life (36-item Short-Form Health Survey, SF-36) were delivered by telephone interviews. Results: The mean BPI intensity and interference scores were higher in the patient group (p=0.04 and 0.004, respectively). All domains of the HAQ instrument tended to score better in the control group, with significant differences in the ?reach? score (p=0.037) and the overall mean score (0.23 vs 0.09; p=0.029). Patients scored worse than controls in several SF-36 dimensions (Role physical, p=0.039; Bodily pain p=0.046; Role emotional, p=0.025). Patients with and without pathogenic variants scored similarly across all tests, without between-group significant differences. Conclusions: Patients with persistently low levels of alkaline phosphatase have significantly worse scores in body pain and other health-related quality of life dimensions, without differences between patients with and without pathogenic variants identified in ALPL gene. This is consistent with the latter ones carrying mutations in regulatory regions.es_ES
dc.description.sponsorshipFunding: The genetic analysis was funded in part by a research grant from Alexiones_ES
dc.format.extent6 p.es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Media S.A.es_ES
dc.rightsAttribution 4.0 International*
dc.rights© 2022 The authors*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceFrontiers in Endocrinology 13:965476es_ES
dc.subject.otherHypophosphatasiaes_ES
dc.subject.otherAlkaline phosphatasees_ES
dc.subject.otherQuality of lifees_ES
dc.subject.otherPatient-reported outcomeses_ES
dc.subject.otherPaines_ES
dc.subject.otherDisabilityes_ES
dc.titlePain and health-related quality of life in patients with hypophosphatasemia with and without ALPL gene mutationses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.3389/fendo.2022.96547es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.3389/fendo.2022.96547es_ES
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Attribution 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International